The SITC Sparkathon – Emerging Leaders, Igniting Innovation is an exciting opportunity for early career professionals seeking to advance their career and the cancer immunotherapy field as a whole.
Following an application process, a group of 30 emerging leaders will explore the critical hurdles that have challenged this field for years. Once projects have been determined, teams will formulate plans to solve the major issues. Participants will have access to elite business coaches/mentors who will assist teams in developing their proposals for successful implementation.
Projects will be presented to a panel of Society for Immunotherapy of Cancer (SITC) leaders who will select the top proposals for implementation.
Click the following links for more information about the SITC Sparkathon, or scroll below to read more.
SITC Sparkathon Matching Donation ChallengeSITC Sparkathon Business CoachesDownload Program Overview
A group of 30 emerging leaders will be selected through an application process to meet for a two-day retreat in a “Technology Hackathon” meets “Shark Tank” format to explore the hurdles and challenges facing the field of cancer immunotherapy with the goal of identifying projects that provide a solution to one or more of the identified hurdles.
The emerging leaders will develop project proposals with guidance from renowned business experts over the two-day period. A panel of judges will award the most promising project(s) $175,000, which the participants will use to implement the project(s) during the following 12-18 months, culminating in a presentation at the society’s 33rd Annual Meeting, Nov. 9 – 11, 2018.
Projects must be collaborative by design throughout implementation. Sample projects may include high-risk (non-preliminary data) projects, methods exchange, whitepapers, business plans, educational and media tools. The 30 participants will emerge as a unique cohort, a dynamic network of young cancer immunotherapy professionals formed to further individual professional development and foster collaborations across institutions and work settings.
The retreat will be held 8 a.m. Aug. 28 – 4:30 p.m. Aug. 29, 2017 in Chicago, IL.
Following the retreat, the cohort will formulate a detailed execution plan including budgets and timelines. The group will be provided with resources of up to $175,000 for project(s) development and implementation. An online communication and project management platform will be provided to further the development of plans on an ongoing basis and foster continued relationship development among the group. The collaborative interface platform will bring like-minded people together in a secure community designed to enable relevant and purposeful interactions, ignite knowledge sharing, drive content creation and improve performance.
The cohort will have approximately 12-18 months to execute project plans. Project outcomes will be considered for publication in the Journal of ImmunoTherapy of Cancer (JITC) and for presentation at the society’s 33rd Annual Meeting, to be held Nov. 9 – 11, 2018 at the Walter E. Washington Convention Center in Washington, District of Columbia.
Be Part of the Breakthrough at the Charles River World Congress on Animal Models in Drug Discovery & Development. Boston | September 26-27, 2017 http://breakthroughs.criver.com/index.html
Use of mAb-based immunotherapies has resulted in major improvements in treatment of B-cell neoplasms, but patients can relapse, succumbing to the disease. An alternative approach that destroys tumor cells including cancer stem cells is, thus, needed urgently. ...
According to the cited pharma company document within, out of Hemel Hempstead, England, May 10, 2017, Dinutuximab beta, originally developed by the Vienna-based biotech company Apeiron Biologics for neuroblastoma, was previously available in Europe under ...
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients. In this exclusive interview with Oncology Central, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org